Cutaneous Manifestations of Inflammatory Bowel Disease

Clinical Pearls for Gastroenterologists

Authors

  • Jennifer Lipson, MD, FRCPC

DOI:

https://doi.org/10.58931/cibdt.2023.1213

Abstract

As clinicians’ knowledge about the relationship between inflammatory bowel diseases (IBDs) and the integumentary system continues to expand, gastroenterologists and dermatologists need to know about the disease associations involved and understand the impact of treatments on these immune conditions in order to provide care to these medically complex patients.

Author Biography

Jennifer Lipson, MD, FRCPC

Dr. Jennifer Lipson is a medical dermatologist in Ottawa practising at West Ottawa Specialty Care. She is a lecturer at the University of Ottawa and an associate physician at The Ottawa Hospital and the Children’s Hospital of Eastern Ontario (CHEO). She serves as a committee member for the Ottawa Dermatology Clinical and Scientific Biannual Meeting, The Royal College of Physicians and Surgeons of Canada Subspecialty Committee for Dermatology and on the Ontario Medical Association Section on Dermatology Executive Committee. Her clinical interests include immune mediated inflammatory diseases, hormonal acne and skin cancer. Dr. Lipson also serves on the medical advisory committee for the Acne and Rosacea Society of Canada.

References

Elisabetta Antonelli, Gabrio Bassotti, Marta Tramontana, Katharina Hansel, Luca Stingeni, Sandro Ardizzone, Giovanni Genovese, Angelo Valerio Marzano and Giovanni Maconi. Dermatological manifestations in inflammatory bowel disease. Journal of Clinical Medicine. 2021 Jan 19;10(2):364. DOI: https://doi.org/10.3390/jcm10020364

Kurtzman DJ, Jones T, Lian F, Peng LS. Metastatic Crohn’s disease: a review and approach to therapy. J Am Acad Dermatol. 2014 Oct;71(4):804-813. DOI: https://doi.org/10.1016/j.jaad.2014.04.002

Loredana Ungureanu, Rodica Cosgerea, Mihail Alexandru Badea, Alina Florentina Vasilovici, Iona Cosgerea and Simona Corina Senila. Cutnaeous manifestation sin inflammatory bowel disease. Experimental and Therapeutic Medicine. 2020;20:31-37. DOI: https://doi.org/10.3892/etm.2019.8321

Roth N, Biedermann L, Fournier N, Butter M, Vavricka SR, Navarini AA, Rogler G, Scharl M; Swiss IBD Cohort Study Group. PLoS One. 2019 Jan 25;14(1):e0210436. DOI: https://doi.org/10.1371/journal.pone.0210436

Barret M, De Parades V, Battistella M, Sokol H, Lemarchaud N, Marteau P. Crohn’s disease of the vulva. J Crohns Colitis. 2014 Jul;8(7):563-570. DOI: https://doi.org/10.1016/j.crohns.2013.10.009

Muhvic-Urek M, Tomac-Stojmenovic M, Mijandrusic-Sincic B. Oral pathology in inflammatory bowel disease. World J Gastroenterol. 2016 Jul 7;22(25):5655-67. DOI: https://doi.org/10.3748/wjg.v22.i25.5655

Yüksel I, Başar Ö, Ataseven H, Ertuğrul İ, Arhan M, İbiş M, Dağlı Ü, Demirel BT, Ülker A, Seçilmiş S, Şaşmaz N. Mucocutaneous manifestations in inflammatory bowel disease. Inflammatory Bowel Diseases. 2009 Apr 1;15(4):546-50. DOI: https://doi.org/10.1002/ibd.20807

Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease- epidemiology, genetics and pathogenesis. Expert Rev Gastroenterol Hepatol. 2019 Apr;13(4):307-317. DOI: https://doi.org/10.1080/17474124.2019.1574569

Joshi TP, Friske SK, Hsiou Da, Duvic M. New Practical aspects of Sweet Syndrome. Am J Clin Dermatol. 2022 May;23(3):301-318. DOI: https://doi.org/10.1007/s40257-022-00673-4

Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, Linos E, Liao W, Haemel A. Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. Journal of the American Academy of Dermatology. 2017 Feb 1;76(2):334-41. DOI: https://doi.org/10.1016/j.jaad.2016.08.012

Cottone M, Sapienza C, Macaluso FS, Cannizzaro M. Psoriasis and Inflammatory Bowel Disease. Dig Dis. 2019;37(6):451-457. DOI: https://doi.org/10.1159/000500116

Lauritano D, Boccalari E, Stasio D, Della Vella F, Carinci F, Lucchese A, Petruzzi M. Prevalence of Oral lesions and correlation with intestinal symptoms of inflammatory bowel disease: A systematic review. Diagnostics(Basel). 2019 Jul 15;9(3):77. DOI: https://doi.org/10.3390/diagnostics9030077

Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti–tumor necrosis factor biologic therapy: a clinical review. Journal of the American Academy of Dermatology. 2009 Sep 1;61(3):486-504. DOI: https://doi.org/10.1016/j.jaad.2008.10.060

Kohorst J, Kimball A, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015 Nov;73(5 Suppl):S27-35. DOI: https://doi.org/10.1016/j.jaad.2015.07.055

Egan CA, Meadows KP, Zone J. Ulcerative colitis and immunobullous disease cured by colectomy. Archives of Dermatology. 1999;135:214-215. DOI: https://doi.org/10.1001/archderm.135.2.214

Chen DH, Zhou HR, Zhang YG, Shen GY, Xu C, Guan CL. Drug induced hypersensitivity syndrome induced by sulfasalazine: A case report. Medicine (Baltimore). 2022 Aug 19;101(33):e30060. DOI: https://doi.org/10.1097/MD.0000000000030060

McNally A, Ibbetson J, Sidhu S. Azathioprine-induced Sweet’s syndrome: A case series and review of the literature. Australas J Dermatol. 2017 Feb;58(1):53-57. DOI: https://doi.org/10.1111/ajd.12383

Romdhane HB, Mokni S, Fathallah N, Slim R, Gharriani N, Sriha B, Ben Salem, C. Sulfasalazine induced sweet’s syndrome. Therapie. 2016 Jun;71(3):345-7. DOI: https://doi.org/10.1016/j.therap.2015.11.006

Azathioprine® Product Monograph, Apotex Inc., Toronto, Ontario. October 28, 2020.

Mesalamine® Product Monograph, Aptalis Pharma Inc., Mont-Saint-Hilaire, Quebec. December 30, 2014.

Hanzel J, Ma C, Casteele NV, Kanna R, Jairath V, Feagan BG. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs. 2021 Feb:81(3):333-347. DOI: https://doi.org/10.1007/s40265-020-01460-3

Dubinsky M, Cross R, Sandborn W, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Arjit Ganguli, Wang A. Extraintestinal manifestations in vedoluzumab and anti-TNF-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018 Aug 16;24(9):1876 - 1882. DOI: https://doi.org/10.1093/ibd/izy065

Chateau T, bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L. Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: A systematic review. J Crohns Colitis. 2019 Dec 10;13(12):1569-1577. DOI: https://doi.org/10.1093/ecco-jcc/jjz095

Fleisher M, Marsal J, Lee S, Frado L, Parian A, Korelitz B , Feagan B. Effects of vedolizumab therapy on extraintestinal manifestastions of inflammatory bowel disease. Dig Dis Sci. 2018 Apr;63(4):825-833. DOI: https://doi.org/10.1007/s10620-018-4971-1

Guedes T, Pedroto I, Lago P. Vedolizumab-associated psoriasis: until where does gut selectivity go? Rev Esp Enferm Dig. 2020 Jul;112(7):580-581. DOI: https://doi.org/10.17235/reed.2020.6817/2019

Downloads

Published

2023-06-28

How to Cite

1.
Lipson J. Cutaneous Manifestations of Inflammatory Bowel Disease: Clinical Pearls for Gastroenterologists. Can IBD Today [Internet]. 2023 Jun. 28 [cited 2024 Nov. 23];1(2):17–23. Available from: https://canadianibdtoday.com/article/view/1-2-lipson

Issue

Volume 1, Issue 2, June 2023

Section

Articles

License

Copyright (c) 2023 Canadian IBD Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.